Cargando…

Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer

Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell-free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR-103a-3p has been reported in several types of human cancer. However, the role...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hui, Bian, Qing-Zhao, Zhang, Wei, Cui, Hai-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669650/
https://www.ncbi.nlm.nih.gov/pubmed/34966454
http://dx.doi.org/10.3892/ol.2021.13156
_version_ 1784614822236651520
author Liu, Hui
Bian, Qing-Zhao
Zhang, Wei
Cui, Hai-Bin
author_facet Liu, Hui
Bian, Qing-Zhao
Zhang, Wei
Cui, Hai-Bin
author_sort Liu, Hui
collection PubMed
description Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell-free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR-103a-3p has been reported in several types of human cancer. However, the role of miR-103a-3p in BC remains unknown. A total of 112 patients with BC and 59 healthy controls were recruited into the present study. The expression level of serum miR-103a-3p was evaluated using reverse transcription-quantitative PCR. Receiver operating characteristic curves were utilized to calculate diagnostic accuracy. Survival curves were generated to analyze survival outcomes. It was found that circulating miR-103a-3p level was upregulated in patients with BC compared with that in healthy controls, and its expression was decreased following surgery. In addition, miR-103a-3p expression level was also associated with advanced clinicopathological features, including positive epidermal growth factor receptor 2 status, metastasis and an advanced TNM stage. The circulating serum miR-103a-3p level could be used to discriminate between patients with BC and the healthy controls prior to surgery using an area under curve [(AUC), 0.697; 95% confidence intervals (CI), 0.615-0.778], and distinguish patients with BC and metastasis from those without metastasis (AUC, 0.936; 95% CI, 0.892-0.980). In addition, high expression level of miR-103a-3p was associated with worse survival outcomes in patients with BC. In conclusion, the present study suggests that miR-103a-3p could be a potential non-invasive diagnostic and prognostic biomarker for BC.
format Online
Article
Text
id pubmed-8669650
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-86696502021-12-28 Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer Liu, Hui Bian, Qing-Zhao Zhang, Wei Cui, Hai-Bin Oncol Lett Articles Breast cancer (BC) is the most frequent cancer for women worldwide. Recently, a spectrum of cell-free circulating microRNAs (miR) has been recognized as promising biomarkers for BC diagnosis and prognosis, among which miR-103a-3p has been reported in several types of human cancer. However, the role of miR-103a-3p in BC remains unknown. A total of 112 patients with BC and 59 healthy controls were recruited into the present study. The expression level of serum miR-103a-3p was evaluated using reverse transcription-quantitative PCR. Receiver operating characteristic curves were utilized to calculate diagnostic accuracy. Survival curves were generated to analyze survival outcomes. It was found that circulating miR-103a-3p level was upregulated in patients with BC compared with that in healthy controls, and its expression was decreased following surgery. In addition, miR-103a-3p expression level was also associated with advanced clinicopathological features, including positive epidermal growth factor receptor 2 status, metastasis and an advanced TNM stage. The circulating serum miR-103a-3p level could be used to discriminate between patients with BC and the healthy controls prior to surgery using an area under curve [(AUC), 0.697; 95% confidence intervals (CI), 0.615-0.778], and distinguish patients with BC and metastasis from those without metastasis (AUC, 0.936; 95% CI, 0.892-0.980). In addition, high expression level of miR-103a-3p was associated with worse survival outcomes in patients with BC. In conclusion, the present study suggests that miR-103a-3p could be a potential non-invasive diagnostic and prognostic biomarker for BC. D.A. Spandidos 2022-01 2021-12-03 /pmc/articles/PMC8669650/ /pubmed/34966454 http://dx.doi.org/10.3892/ol.2021.13156 Text en Copyright: © Liu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Liu, Hui
Bian, Qing-Zhao
Zhang, Wei
Cui, Hai-Bin
Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer
title Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer
title_full Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer
title_fullStr Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer
title_full_unstemmed Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer
title_short Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer
title_sort circulating microrna-103a-3p could be a diagnostic and prognostic biomarker for breast cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669650/
https://www.ncbi.nlm.nih.gov/pubmed/34966454
http://dx.doi.org/10.3892/ol.2021.13156
work_keys_str_mv AT liuhui circulatingmicrorna103a3pcouldbeadiagnosticandprognosticbiomarkerforbreastcancer
AT bianqingzhao circulatingmicrorna103a3pcouldbeadiagnosticandprognosticbiomarkerforbreastcancer
AT zhangwei circulatingmicrorna103a3pcouldbeadiagnosticandprognosticbiomarkerforbreastcancer
AT cuihaibin circulatingmicrorna103a3pcouldbeadiagnosticandprognosticbiomarkerforbreastcancer